Summary
Twenty four patients with high grade malignant NHL (stage II 8, stage III 4, stage IV 12 patients respectively) were treated with a response-oriented regimen: Treatment was initiated according to the CHOP-protocol. Patients achieving at least a partial remission after 2 and a complete remission (CR) after 4 cycles were continued on CHOP to a total of 9 cycles. Patients not meeting these criteria were switched to a combination of Etoposide, Ifosfamide, Methotrexate, and Bleomycin (VIM-Bleo). With CHOP treatment, 16 patients (67%) achieved a CR. Of the remaining 8, 7 were treated with VIM-Bleo; 5 of these entered CR for a overall CR rate of 21/24 (88%). With a median follow up of 28 months 7 patients relapsed: 6 relapses occurred in patients with a rapid initial response and treated only with CHOP. We conclude, that there is a significant risk of relapse even in patients readily responding to CHOP and that consolidation therapy with a non cross-resistant regimen may improve results in these patients.
This is a preview of subscription content, log in via an institution to check access.
References
Armitage JO, Corder MP, Leimert JT, Dick FR, Elliott TE (1980) Advanced diffuse histiocytic lymphoma treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) without maintenance therapy. Cancer Treat Rep 64: 649–654
Busch FW, Krüger HU, Kraft A, Arnold H, Heim M, Günther E, Steinke B (1987) Combination of Ifosfamide, Methotrexate, VP-16, and Bleomycin (IMV-Bleo) as salvage therapy for non-Hodgkin's lymphoma. Contrib Oncol 26: 425–430
Cabanillas F, Burgess MA, Bodey GP, Freireich EJ (1983) Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. Am J Med 74: 382–388
Coltman CA, Dahlberg S, Jones SE, Miller TP, Dana BW, McKelvey EM, Hartsock RJ, Dixon DO (1986) CHOP is curative in thirty percent of patients with diffuse large cell lymphoma: a twelve year Southwest Oncology Group follow up. Proc ASCO 5: Abstr 774
Fisher RI, DeVita VT, Hubbard SM, Longo DL, Wesley R, Chabner BA, Young RC (1983) Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 98: 304–309
Gerard-Marchant R, Hamlin I, Lennert K, Rilke F, Stansfield AG, Unnik JAM (1974) Classification of non-Hodgkin's lymphomas. Lancet II: 406–408
Hagberg H, Björkholm M, Glimelius B, Lindemalm Ch, Mellstedt H, Killander A (1985) CHOP vs MEV for the treatment of non-Hodgkin's lymphoma of unfavourable histopathology: a randomized clinical trial. Eur J Cancer Clin Oncol 21: 175–179
Kaplan RS, Meier P (1959) Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 457–481
Klimo P, Connors JM (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102: 596–602
McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE (1976) Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38: 1484–1493
WHO Handbook for reporting results of cancer treatment. WHO Offset Publ. 48 (Geneva, 1978)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steinke, B., Krüger, H.U., Kraft, H. et al. Response-oriented therapy with CHOP and VIM-Bleo in high-grade malignant non-Hodgkin's lymphomas. Blut 56, 269–271 (1988). https://doi.org/10.1007/BF00320288
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320288